This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
by Zacks Equity Research
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
NPCEPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
earnings medical medical-devices
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?
by Moumi Mondal
TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.
TEMNegative Net Change NTRANegative Net Change GHNegative Net Change
medical medical-devices
CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook
by Zacks Equity Research
Cardinal Health targets 13%-15% fiscal 2027 EPS growth as pharma demand normalizes and specialty, At-Home and buybacks remain key priorities for execution.
CAHNegative Net Change
dental earnings medical-devices
Addus HomeCare (ADUS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ADUSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Impinj (PI) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
by Urbi Guha
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
INGNNegative Net Change RMDNegative Net Change INSPPositive Net Change
medical medical-devices
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
by Urbi Guha
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
INGNNegative Net Change PHGPositive Net Change RMDNegative Net Change
medical medical-devices
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
by Zacks Equity Research
Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.
CAHNegative Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
earnings medical medical-devices
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside
by Zacks Equity Research
TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.
TEMNegative Net Change
earnings medical-devices
RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised
by Zacks Equity Research
RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.
RDNTNegative Net Change CAHNegative Net Change COOPositive Net Change WSTNegative Net Change
earnings medical medical-devices